Return to Results

Phase III Chemoprevention Trial Of Selenium Supplementation In Persons With Resected Stage I Non-Small Cell Lung Cancer

new search

Trial Conditions
  • Lung Cancer
What is the purpose of this trial?

RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. It is not yet known if selenium is effective in preventing the growth of new tumors in patients with previously resected non-small cell lung cancer. PURPOSE: This randomized phase III trial is studying selenium to see how well it works compared to a placebo in preventing the development of second primary lung tumors in patients who have undergone surgery to remove stage I non-small cell lung cancer.

Date & Status

Active, not recruiting

Who can Participate?


18 and older




- Histologically confirmed, completely resected stage IA (pT1, N0) or IB (pT2, N0)
non-small lung cancer (except carcinoid)*

- Completion of treatment for stage I lung cancer within the past 6 to 36 months
and currently disease free

- At least one mediastinal lymph node sampled at resection NOTE: *SWOG and CALGB
patients must be T1, N0; CALGB patients may be T2, N0 provided disease was
completely resected prior to June 1, 2001 and participation in CALGB 9633 was
refused if offered

- No evidence of new or recurrent lung cancer on chest x-ray within the past 8 weeks

- No synchronous lung or non-lung lesions or metastasis, even if resectable

- No history of more than one primary lung cancer at any time



- 18 and over

Performance status:

- ECOG 0-1

Life expectancy:

- Not specified


- Not specified


- Bilirubin no greater than upper limit of normal (ULN)

- SGOT or SGPT no greater than ULN


- Not specified


- No concurrent or other prior cancer within the past 5 years except localized
non-melanoma skin cancer


Biologic therapy:

- Not specified


- No prior or concurrent chemotherapy for recurrent lung cancer

Endocrine therapy:

- Not specified


- No prior or concurrent radiotherapy for recurrent lung cancer


- See Disease Characteristics

- No concurrent surgery


- Prior mineral, herbal, phytochemical, or vitamin supplementation allowed

- No concurrent supplement(s) containing more than 50 micrograms of selenium

- Concurrent non-selenium containing mineral, herbal, phytochemical, or vitamin
supplementation allowed if schedule and supplementation prior to study remains

Gender: Both
Steward Physician(s)
  • Daniel D. Karp, MD
  • Omer Kucuk, MD
  • Randolph S. Marks, MD
  • Michael R. Johnston, MD, FRCSC
  • Gerald H. Clamon, MD
  • Gord Okawara, MD
  • St. Elizabeth's Medical Center - Active, not recruiting
  • Norwood Hospital - Active, not recruiting
Trial Interventions
Dietary Supplement
  • selenium
  • placebo
Physician Researcher

Investigator Name:

  • Daniel D. Karp, MD
  • Omer Kucuk, MD
  • Randolph S. Marks, MD
  • Michael R. Johnston, MD, FRCSC
  • Gerald H. Clamon, MD
  • Gord Okawara, MD

Other Information

Sponsor: Eastern Cooperative Oncology Group
Phase: Phase 3
Trial ID: NCT00008385
Volunteers:  Not Accepting Healthy Volunteers

new search

Connect with Steward

Visit Our Twitter Feed Visit Our Facebook Page Email This Page Print This Page

Subscribe to our patient e-newsletter

Copyright © 2015 Steward Health Care
Connect Healthcare Panacea CMS Solutions